Therapy with mosunetuzumab, a bispecific antibody for relapsed/refractory hairy cell leukemia

References

• Robak T, Matutes E, Catovsky D, et al. Hairy cell leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26 Suppl 5(Supplement 5):v100–v107. doi:10.1093/annonc/mdv200
   PubMedGoogle Scholar
• Inbar M, Herishanu Y, Goldschmidt N, et al. Hairy cell leukemia: retrospective analysis of demographic data and outcome of 203 patients from 12 medical centers in Israel. Anticancer Res. 2018;38(11):6423–6429. doi:10.21873/anticanres.13003
   PubMed Web of Science ®Google Scholar
• Stetler-Stevenson M, Tembhare PR. Diagnosis of hairy cell leukemia by flow cytometry. Leuk Lymphoma. 2011;52 Suppl 2(sup2):11–13. doi:10.3109/10428194.2011.570820
   PubMedGoogle Scholar
• Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011;364(24):2305–2315. doi:10.1056/NEJMoa1014209
   PubMed Web of Science ®Google Scholar
• Else M, Dearden CE, Matutes E, et al. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol. 2009;145(6):733–740. doi:10.1111/j.1365-2141.2009.07668.x
   PubMed Web of Science ®Google Scholar
• Kraut E. Infectious complications in hairy cell leukemia. Leuk Lymphoma. 2011;52 Suppl 2(sup2):50–52. doi:10.3109/10428194.2011.570819
   PubMedGoogle Scholar
• Levy I, Tadmor T. Time to cure hairy cell leukemia. Turk J Haematol. 2017;34(4):289–290. doi:10.4274/tjh.2017.0296
   PubMed Web of Science ®Google Scholar
• Chihara D, Kreitman RJ. Treatment of hairy cell leukemia. Expert Rev Hematol. 2020;13(10):1107–1117. doi:10.1080/17474086.2020.1819231
   PubMed Web of Science ®Google Scholar
• Ravandi F. Chemoimmunotherapy for hairy cell leukemia. Best Pract Res Clin Haematol. 2015;28(4):230–235. doi:10.1016/j.beha.2015.09.005
   PubMed Web of Science ®Google Scholar
• Chihara D, Kantarjian H, O'Brien S, et al. Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial. Br J Haematol. 2016;174(5):760–766. doi:10.1111/bjh.14129
   PubMed Web of Science ®Google Scholar
• Chihara D, Arons E, Stetler-Stevenson M, et al. Randomized phase II study of first-line cladribine with concurrent or delayed rituximab in patients with hairy cell leukemia. J Clin Oncol. 2020;38(14):1527–1538. doi:10.1200/JCO.19.02250
   PubMed Web of Science ®Google Scholar
• Tiacci E, Park JH, De Carolis L, et al. Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia. N Engl J Med. 2015;373(18):1733–1747. doi:10.1056/NEJMoa1506583
   PubMed Web of Science ®Google Scholar
• Cross MJ, Shah P, Heelan K, et al. Dabrafenib is a safe and effective therapy in relapsed/refractory classical hairy cell leukemia. Blood. 2020;136(Supplement 1):7–8. doi:10.1182/blood-2020-137531
   Google Scholar
• Park AJH, Devlin S, Ph D, et al. Vemurafenib and obinutuzumab as frontline therapy for hairy cell leukemia. NEJM Evid. 2023;2(10):EVIDoa2300074.
   Google Scholar
• Tiacci E, De Carolis L, Simonetti E, et al. Vemurafenib plus rituximab in refractory or relapsed hairy-cell leukemia. N Engl J Med. 2021;384(19):1810–1823. doi:10.1056/nejmoa2031298; Falini B, De Carolis L, Tiacci E. How Itreat refractory/ relapsed hairy cell leukemia with BRAF inhibitors. Blood. 2022;139(15):2294–2305. doi:10.1182/blood.2021013502
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Moreau P, Hutchings M, et al. Treatment with combination of dabrafenib and trametinib in patients with recurrent/refractory BRAF V600E-Mutated hairy cell leukemia (HCL). Blood. 2018;132(Supplement 1):391–391. doi:10.1182/blood-2018-99-113135
   Google Scholar
• Kreitman RJ, Dearden C, Zinzani PL, et al. Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. Leukemia. 2018;32(8):1768–1777. doi:10.1038/s41375-018-0210-1
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Dearden C, Zinzani PL, et al. Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial. J Hematol Oncol. 2021;14(1):35. doi:10.1186/s13045-020-01004-y
   PubMed Web of Science ®Google Scholar
• Rogers KA, Andritsos LA, Wei L, et al. Phase 2 study of ibrutinib in classic and variant hairy cell leukemia. Blood. 2021;137(25):3473–3483. doi:10.1182/blood.2020009688
   PubMed Web of Science ®Google Scholar
• Grever MR, Abdel-Wahab O, Andritsos LA, et al. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood. 2017;129(5):553–560. doi:10.1182/blood-2016-01-689422
   PubMed Web of Science ®Google Scholar
• Omer MH, Shafqat A, Ahmad O, et al. Bispecific antibodies in hematological malignancies: a scoping review. Cancers (Basel). 2023;15(18):4550. doi:10.3390/cancers15184550
   PubMed Web of Science ®Google Scholar
• https://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-lunsumio-mosunetuzumab-axgb-adult-patients-relapsed-or.
   Google Scholar
• Huang S, van Duijnhoven SMJ, Sijts AJAM, van Elsas A. Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy. J Cancer Res Clin Oncol. 2020 Dec;146(12):3111-3122.
   Google Scholar